120 related articles for article (PubMed ID: 3463436)
1. Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.
Speth PA; Linssen PC; Beex LV; Boezeman JB; Haanen C
Cancer Chemother Pharmacol; 1986; 18(1):78-82. PubMed ID: 3463436
[TBL] [Abstract][Full Text] [Related]
2. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion.
Speth PA; Linssen PC; Holdrinet RS; Haanen C
Clin Pharmacol Ther; 1987 Jun; 41(6):661-5. PubMed ID: 3581649
[TBL] [Abstract][Full Text] [Related]
3. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.
Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
Cancer Chemother Pharmacol; 1987; 20(4):305-10. PubMed ID: 3480081
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.
Mader RM; Zilg H; Schlappack O; Steger GG; Baur M; Greifenberg B; Heberle U; Dittrich C
Cancer Chemother Pharmacol; 1995; 37(1-2):91-6. PubMed ID: 7497603
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
Miller AA; Schmidt CG
Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
[TBL] [Abstract][Full Text] [Related]
6. [Intra-arterial infusion chemotherapy in the treatment of advanced breast cancer--doxorubicin versus epirubicin].
Yayoi E; Furukawa J; Takatsuka Y; Kobayashi T; Aikawa T; Maeura Y; Kaji M; Kotsuma Y
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1621-4. PubMed ID: 1530320
[TBL] [Abstract][Full Text] [Related]
7. Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).
Raijmakers R; Speth P; de Witte T; Linssen P; Wessels J; Haanen C
Br J Cancer; 1987 Aug; 56(2):123-6. PubMed ID: 3663464
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
9. [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].
Ehninger G; Stocker HJ; Proksch B; Wilms K
Klin Wochenschr; 1980 Sep; 58(18):927-34. PubMed ID: 7206588
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.
Eksborg S; Stendahl U; Lönroth U
Eur J Clin Pharmacol; 1986; 30(5):629-31. PubMed ID: 3463510
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells.
Kohnoe S; Yoshida M; Takahashi I; Emi Y; Maehara Y; Sugimachi K
Anticancer Res; 1992; 12(2):389-92. PubMed ID: 1580555
[TBL] [Abstract][Full Text] [Related]
13. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
Leca F; Marchiset-Leca D; Noble A; Antonetti M
Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.
Eksborg S; Andersson M; Domellöf L; Lönroth U
Med Oncol Tumor Pharmacother; 1986; 3(2):105-10. PubMed ID: 3462442
[TBL] [Abstract][Full Text] [Related]
15. Preliminary phase I study of 4'-epi-adriamycin.
Bonfante V; Bonadonna G; Villani F; Di Fronzo G; Martini A; Casazza AM
Cancer Treat Rep; 1979 May; 63(5):915-8. PubMed ID: 455333
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.
Sweatman TW; Israel M
Cancer Chemother Pharmacol; 1987; 19(3):201-6. PubMed ID: 3472675
[TBL] [Abstract][Full Text] [Related]
17. [Phase I-II study of hepatic intraarterial one-shot administration of adriamycin in patients with metastatic liver cancer].
Horikoshi N; Ogawa M; Tabata M; Inoue K; Mukaiyama T; Fukutani H; Hirano A; Mizunuma N; Itami S; Oohashi K
Gan To Kagaku Ryoho; 1991 May; 18(6):977-82. PubMed ID: 2029200
[TBL] [Abstract][Full Text] [Related]
18. [Intra-arterial infusion chemotherapy with adriamycin for the treatment of locally advanced breast cancer--studies of serum and tissue concentrations of adriamycin].
Takatsuka Y; Imamotoh H; Tsuchiyama M; Numata N; Kawahara T
Gan To Kagaku Ryoho; 1982 May; 9(5):880-7. PubMed ID: 7184432
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic studies of THP-ADM (tetrahydropyranyl adriamycin)].
Majima H; Iguchi H; Tone H
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):542-8. PubMed ID: 3954376
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours.
Lee HJ; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):299-306. PubMed ID: 9261889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
